SCHEMBL190551

SCHEMBL190551

Clc1cc(OCc2ccccc2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.53
CYP3A4 P08684 1/20 0.51
MAOB P27338 7/20 0.50
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
BCHE P06276 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
PTGS1 P23219 1/20 0.47
SLC6A2 P23975 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MAOA P21397 3/20 0.47
MAPK14 Q16539 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NSD2 O96028 1/20 0.46
ABL1 P00519 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30339592 1.00 ALOX5 (0.53) ALOX5CYP3A4MAOBCYP4F2CYP4A11
SCHEMBL31336124 0.97 ALOX5 (0.50) ALOX5CYP3A4MAOBCYP4F2CYP4A11
SCHEMBL4367998 0.89 LMNA (0.49) ALOX5CYP3A4MAOBBCHELMNA
SCHEMBL988721 0.86 MAOB (0.51) MAOBMAOANR4A2SMN1; SMN2
SCHEMBL1645560 0.85 LNPEP (0.46) ALOX5CYP3A4MAOBMAOARAB9A
SCHEMBL21477167 0.85 LOXL2 (0.43) ALOX5CYP3A4MAOBLMNACYP1A2
SCHEMBL2567241 0.83 MAPK1 (0.50) LMNAMAOAMAPTSMN1; SMN2
SCHEMBL21464127 0.83 TDP1 (0.46) ALOX5CYP3A4L3MBTL1
SCHEMBL30892105 0.83 TDP1 (0.46) ALOX5CYP3A4L3MBTL1
SCHEMBL989460 0.83 GRM5 (0.52) MAOBMAOANR4A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116102491-A Application of metal catalytic coupling by continuous flow technology 浙江晖石药业有限公司 2023-05-12 CN claimed
US-20260102395-A1 INHIBITING HISTONE DEACETYLASE 6 EIKONIZO THERAPEUTICS, INC. (US) 2026-04-16 US disclosed
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2026-02-26 US disclosed
US-12522583-B2 Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-01-13 US disclosed
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
US-20250230166-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2025-07-17 US disclosed
WO-2025090480-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-05-01 WO disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME LLC (US) 2025-02-20 US disclosed
US-20090197901-A1 VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS PHARMA MAR, S.A. (ES) 2009-08-06 US disclosed
US-7495000-B2 Variolin derivatives and their use as antitumor agents PHARMA MAR, S.A. (ES) 2009-02-24 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
EP-1971601-A2 N4-PHENYL-QUINAZOLINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES Array Biopharma Inc. (US) 2008-09-24 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed
WO-2007059257-A2 N4-PHENYL-QUINAZ0LINE-4 -AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2007-05-24 WO disclosed
US-5869428-A CONTROLLING WEEDS ISHIHARA SANGYO KAISHA LTD. (JP) 1999-02-09 US disclosed
CN-1139109-A Pyridonesulfonylurea compounds, process for their production and herbicides containing them ISHIHARA SANGYO KAISHA (JP) 1997-01-01 CN disclosed
EP-0733629-A1 Pyridonesulfonylurea compounds, process for their production and herbicides containing them ISHIHARA SANGYO KAISHA, LTD. (JP) 1996-09-25 EP disclosed
US-5484761-A PRE OR POSTEMERGENT HERBICIDES MONSANTO COMPANY (US) 1996-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A ALOX5 1604/4885CYP3A4 1828/4885MAOB 2885/4885
US-20250230166-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 ALOX5 4610/4885CYP3A4 4388/4885MAOB 570/4885
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC9 ALOX5 4852/4885CYP3A4 4406/4885MAOB 1479/4885
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, CTTN ALOX5 4816/4885CYP3A4 3619/4885MAOB 1133/4885
US-20260102395-A1 INHIBITING HISTONE DEACETYLASE 6 HDAC6, HDAC1, HDAC8 ALOX5 4652/4885CYP3A4 3860/4885MAOB 795/4885
US-20250059220-A1 SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF SULT1E1, TPMT, SULT1A1 ALOX5 2062/4885CYP3A4 14/4885MAOB 1813/4885
US-20090197901-A1 VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS CBR3, CCNL2, HRH3 ALOX5 1420/4885CYP3A4 1040/4885MAOB 1436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.